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Background: Coronary CT angiography (CTA) is an established tool to rule out coronary
artery disease. Performance of coronary CTA is highly dependent on patients’ heart rates
(HRs). Despite widespread use of b-blockers for coronary CTA, few studies have compared
various agents used to achieve adequate HR control.
Objective: We sought to assess if the ultrashort-acting b-blocker intravenous esmolol is at
least as efficacious as the standard of care intravenous metoprolol for HR control during
coronary CTA.
Methods: Patients referred to coronary CTA with a HR >65 beats/min despite oral meto-
prolol premedication were enrolled in the study. We studied 412 patients (211 male; mean
age, 57  12 years). Two hundred four patients received intravenous esmolol, and 208
received intravenous metoprolol with a stepwise bolus administration protocol. HR and
blood pressure were recorded at arrival, before, during, immediately after, and 30 minutes
after the coronary CTA scan.
Results: Mean HRs of the esmolol and metoprolol groups were similar at arrival (78  13
beats/min vs 77  12 beats/min; P ¼ .65) and before scan (68  7 beats/min vs 69  7 beats/
min; P ¼ .60). However, HR during scan was lower in the esmolol group vs the metoprolol
group (58  6 beats/min vs 61  7 beats/min; P < .0001), whereas HRs immediately and
30 minutes after the scan were higher in the esmolol group vs the metoprolol group (68  7
beats/min vs 66  7 beats/min; P ¼ .01 and 65  8 beats/min vs 63  8 beats/min; P < .0001;ontributed equally to this study.
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intravenous esmolol vs 162 of 208 of the patients (78%) who received intravenous meto-
prolol (P < .05). Of note, hypotension (systolic BP <100 mm Hg) was observed right after the
scan in 19 patients (9.3%) in the esmolol group and in 8 patients (3.8%) in the metoprolol
group (P < .05), whereas only 5 patients (2.5%) had hypotension 30 minutes after the scan in
the esmolol group compared to 8 patients (3.8%) in the metoprolol group (P ¼ .418).
Conclusion: Intravenous esmolol with a stepwise bolus administration protocol is at least as
efficacious as the standard of care intravenous metoprolol for HR control in patients who
undergo coronary CTA.
ª 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction proportions of patients who achieve the target HR of 65Coronary CT angiography (CTA) with its high sensitivity and
high negative predictive value is an established diagnostic tool
for the evaluation of coronary artery disease.1,2 Despite the
great advances in scanner technology, the image quality
remains highly dependent on heart rate (HR) and the regu-
larity of cardiac rhythm.3e5 Current guidelines recommend
that HR should be<65 beats/min and optimally<60 beats/min
to achieve excellent image quality and low effective radiation
dose.6 Metoprolol is the first-line intravenous (IV) b-blocker for
HR lowering in patients undergoing coronary CTA.7e9 How-
ever, a recent survey has revealed that 50% of centers allow an
HR >70 beats/min for coronary CTA, mainly because of con-
cerns regarding potential side effects of b-blocker adminis-
tration (mainly hypotension and bradycardia).10 The half-life
of IV metoprolol is approximately 3 to 7 hours; therefore, if
adverse effect occurs as a result of the HR-lowering medica-
tion, it may debilitate the patient for hours.11 These data
indicate the need for a safe, short-lasting HR control in the
scanner rooms.
Esmolol is an ultrashort-acting cardioselective IV b-recep-
tor blocking agentwith a rapid onset (within 2e3minutes) and
ultrashort duration of action (mean half-life [t1/2] ¼ 9 mi-
nutes).11,12 The rapid onset and offset of effects of esmolol
provide an element of safety not previously available with
longer-acting b-adrenoceptor antagonists.13 During coronary
CTA, short and effective HR control is desirable; therefore,
esmolol might be a good alternative to the standard of care
metoprolol. Currently, esmolol is routinely administered in
the intensive care unit for the treatment of acute supraven-
tricular arrhythmias; however, administration before coro-
nary CTA for HR reduction is an “off-label” indication. In an
observational study, Degertekin et al14 used 50 mg of oral
b-blocker (atenolol) in combination with IV esmolol 1 to
2 mg/kg (range, 50-300 mg) and reported a 65% responder rate
with regard to achieving a HR of<65 beats/min. There is a lack
of evidence regarding the efficacy and safety of IV esmolol
administered in a body weight-independent, stepwise bolus
protocol. Furthermore, no direct comparison of esmolol vs
metoprolol administration for HR control during coronary
CTA is available.
We sought to investigate if the ultrashort half-life IV
esmolol is at least as efficacious as the standard of care IV
metoprolol for HR reduction during coronary CTA. Therefore,
the primary objective of this clinical trial was to compare thebeats/min during the coronary CTA image acquisition in the
esmolol vs metoprolol groups. As the secondary objective, we
sought to estimate the incidence of bradycardia (defined as
HR <50 beats/min) or hypotension (defined as systolic blood
pressure [BP] <100 mm Hg) as an effect of b-blockers in the
esmolol and metoprolol groups.2. Materials and methods
The study complied with the Declaration of Helsinki. The
National Institute for Pharmacy and the institutional review
board approved the study. Informed consent was obtained
from all patients. The authors had full control of the data and
the information submitted for publication. The study was
designed and implemented in accordance with the CONSORT
statement, elaborated for randomized, controlled trials.15
2.1. Study design
This is a randomized single-center noninferiority phase III
clinical trial comparing two IV b-adrenergic receptor blockers
to reduce HR in patients who undergo coronary CTA because
of suspected coronary artery disease (European Union Clinical
Trials Register number: 2013-000048-24). The noninferiority
margin was set on 10% because we assumed that the differ-
ence between the two groups in proportion of responder pa-
tients (patients achieving 65 beats/min) less than this is
clinically irrelevant. The primary endpoint was the proportion
of patients who reached HR 65 beats/min in the esmolol
group. The secondary endpoint was the proportion of patients
who experienced bradycardia (HR <50 beats/min) and/or hy-
potension (systolic BP <100 mmHg) as an effect of b-blockers.
We have performed an interim analysis after 45 days to
ensure adequate enrollment rate and to assess toxicity as well
as adverse events. An adverse event was defined as a change
in health condition resulting from the administration of
b-blockers, which is not resolving with observation and
requires medical intervention.
2.2. Study population
Patients who were referred to coronary CTA because of sus-
pected coronary artery disease and had an HR >65 beats/min
despite oral metoprolol pretreatment were enrolled in the
Fig. 1 e Flow chart of the study. bpm, Beats/min; CCTA,
coronary CT angiography; HR, heart rate; IV, intravenous.
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implanted stent with a diameter 3 mm or previous coronary
artery bypass surgery were eligible to participate in the
study.16 Individuals with a heart rhythm other than sinus
rhythm, any contraindication against b-blocker (asthma
bronchiale, chronic obstructive pulmonary disease, any type
of documented atrioventricular block, severe aortic valve
stenosis, severe left ventricular dysfunction characterized by
ejection fraction below 30%), or a systolic BP <100 mm Hg
before the coronary CTA scan were excluded from the study.
2.3. Drug administration protocol and HR monitoring
Patients received 50-mg oral metoprolol at arrival if the HR
was >65 beats/min. If the HR was 80 beats/min, 100-mg oral
metoprolol was administered. The HR was re-evaluated
60 minutes after the oral b-blockade, immediately before the
coronary CTA examination. Patients presenting with an HR
>65 beats/min on the CT table were randomized to IV esmolol
or IV metoprolol administration. In both the investigational
(esmolol) and the active control (metoprolol) groups, the IV
drug was administered by the physician performing the cor-
onary CTA scan. To achieve randomization, we administered
IV esmolol on even weeks and metoprolol on odd weeks in an
alternating fashion. The IV metoprolol (Betaloc; 1 mg/mL;
AstraZeneca, Luton, United Kingdom; 5-mg ampoule) was
titrated in 5-mg doses in every 3 minutes until the target HR
(65 beats/min) or the maximum dose of metoprolol (20 mg)
was achieved.1 The IV esmolol (Esmocard; 2500 mg/10 mL;
AOP Orphan Pharmaceuticals AG, Vienna, Austria) was
diluted to 500 mg/10 mL and titrated in ascending 100-, 200-,
200-mg doses in every 3 minutes until the target HR (65
beats/min) or the maximum dose of esmolol (500 mg) was
achieved. BP was monitored before every administered drug
bolus. If hypotension (defined as systolic BP <100 mm Hg) or
bradycardia (defined as HR <50 beats/min) was measured, the
administration of the b-blocker agent was suspended. Two
puffs of sublingual nitroglycerine were given to each patient 3
to 5 minutes before the CT scan to ensure the proper visuali-
zation of the coronaries. The HR was recorded at arrival (T1),
immediately before coronary CTA (T2), during breathhold,
contrast injection, and scan (TS), immediately after scan (T3),
and 30 minutes after coronary CTA scan (T4). BP was
measured at T1, T2, T3, and T4 time points. The study flow
chart is summarized in Figure 1.
2.4. Scan protocol
All examinations were performed with 256-slice CT (Brilliance
iCT 256; Philips Healthcare, Best, the Netherlands). Contrast-
enhanced image acquisition was performed in inspiration
during a single breathhold in craniocaudal direction. Imag-
ing parameters were used as follows: slice collimation of
128 mm  0.625 mm, rotation time of 270 ms, tube voltage of
80 to 120 kV, and tube current of 150 to 300 mAs depending on
patients’ body mass index. The images were acquired using
prospective electrocardiogram triggering at 75% to 81% phase
(3% padding). The iodinated contrast agent (Iomeron 400;
Bracco Ltd, Milan, Italy) was injected into an antecubital vein
via an 18-ga cannula using a dual-syringe technique, at a flowrate of 3.5 to 5.5 mL/s depending on patients’ bodymass index
and the tube voltage. Bolus tracking was used with a region of
interest placed in the left atrium. Images were reconstructed
with a slice thickness of 0.8 mm and 0.4-mm increment.
2.5. Statistical analysis
The sample size calculationwas based on a recently published
study, which showed that 83% of patients who received
metoprolol premedication achieved an HR of 65 beats/min
during coronary CT angiography.17 The noninferiority margin
was set to 10% because we have assumed that this is a clini-
cally acceptable maximum difference between the responder
proportions of the two treatment groups. Degertekin et al14
reported that 65% of the patients achieved the target HR of
65 beats/min after administration of intravenous esmolol.
However, Degertekin et al administered smaller doses; thus,
our primary aim to achieve at least 73% responder proportion
seemed to be realistic. Dedicated software was used for
sample size calculation (East, version 5.4.1; Cytel Inc, Cam-
bridge, Massachusetts). A total of 595 patients, 297 to 298 pa-
tients on each treatment arm, were needed to show that the
difference between proportion of responders in metoprolol
group vs esmolol group is less than the noninferiority margin
set at 10% with a power of 90% using a 1-sided P ¼ .025 level
test. The sample size calculation was based on an intention to
treat analysis.
Continuous variables were reported as mean  standard
deviation. Categorical variables are given in frequency.
According to the Shapiro-Wilk tests, some of the parameters
showed mild deviation from normal distribution. To deal
with the non-normality, the groups were compared by robust
t tests using 20%-trimmed means with bootstrapping.18 Dif-
ferences of categorical variables between treatment groups
were analyzed by chi-square tests. With respect to all
statistical tests, a 2-sided P-value of <.05 was considered
significant. Statistical analyses were performed with R,
version 3.0.2 (R Foundation for Statistical Computing, Vienna,
Austria).
Table 2 e Heart rate.
Time point Esmolol
(n ¼ 204)
Metoprolol
(n ¼ 208)
P
Mean  SD Mean  SD
T1 78  13 77  12 .652
T2 68  7 69  7 .599
TS 58  6 61  7 <.0001
T3 68  7 66  7 <.01
T4 65  8 63  8 <.0001
Heart rate measured (in beats/min) at T1 (arrival), T2 (before scan),
TS (during scan), T3 (after scan), and T4 (emission).
Statistics: robust, independent t test.
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We have stopped the patient enrollment early as the interim
analysis indicated that IV esmolol is clearly noninferior to IV
metoprolol, and in fact, esmolol showed superiority charac-
teristics compared to IV metoprolol in reducing HR during
coronary CTA. Between April 2013 and September 2013, in
total, 650 consecutive patients referred to coronary CTA were
screened, and of these, 574 patients were eligible to partici-
pate in the study. In 162 patients no IV drug was administered
because the HR before scan was 65 beats/min. In total, 412
patients (with HR >65 beats/min before the scan) were
enrolled and randomized into either esmolol or metoprolol
group; 204 received IV esmolol and 208 patients received IV
metoprolol. There was no difference between the two groups
regarding the clinical characteristics (Table 1).
In the esmolol group, 53 of 204 patients (26.0%) received 1
bolus (100 mg), 73 of 204 (35.8%) received 2 boluses (300 mg),
and 78 of 204 (38.2%) received 3 boluses (500mg) of esmolol. In
the metoprolol group, IV metoprolol was administered in a
similar fashion as in the esmolol group but in 5-mg in-
crements. Eighty-three of 208 patients (39.9%) received 1 bolus
(5 mg), 45 of 208 patients (21.6%) 2 boluses (10 mg), 53 of 208
(25.5%) 3 boluses (15 mg), and 27 of 208 (13.0%) 4 boluses
(20 mg) of metoprolol.
Oral metoprolol administration was similar in the esmolol
and metoprolol groups (51.2  33.1 vs 52.4  33.6; P ¼ .71). On
average, 325.6  158.4 mg IV esmolol and 10.7  6.3 mg IV
metoprolol were administered.
The mean HRs of the esmolol and metoprolol groups were
similar at the time of arrival (T1: 78  13 vs 77  12 beats/min;
P ¼ .65) and immediately before the coronary CTA examina-
tion (T2: 68  7 vs 69  7 beats/min; P ¼ .60). However, HR
during the scan was significantly lower among the patients
who received IV esmolol vs patients who received IV meto-
prolol (TS: 58  6 vs 61  7 beats/min; P < .0001). On the
other hand, HRs immediately after the coronary CTA andTable 1 e Demographic characteristics of study groups.
Characteristic Esmolol
(n ¼ 204)
Metoprolol
(n ¼ 208)
P
Age (y), mean  SD 56.9  10.8 57.6  12.2 .390
Male/female 100/104 111/97 .377
BMI (kg/m2), mean  SD 28.4  4.9 28.2  4.7 .956
Hypertension (%) 67 66 .889
Diabetes (%) 16 14 .603
Dyslipidemia (%) 48 55 .154
AMI (%) 5 10 .076
PCI (%) 5 7 .455
CABG (%) 4 6 .287
PAD (%) 9 8 .801
Stroke (%) 4 1 .072
Smoking (%) 25 26 .845
b-Blocker (%) 47 48 .795
AMI, acute myocardial infarction; BMI, body mass index; CABG,
coronary artery bypass graft; PAD, peripheral arterial disease; PCI,
percutaneous coronary intervention.
Statistics: robust, independent t test and chi-square test.30 minutes after the coronary CTA were higher in the esmolol
group than in the metoprolol group (T3: 68  7 vs 66  7 beats/
min; P < .01; and T4: 65  8 vs 63  8 beats/min; P < .0001,
respectively; Table 2; Fig. 2). Systolic and diastolic BPs showed
no difference between the 2 groups measured at any time
point (Table 3).
HR of 65 beats/min was reached in 182 of 204 (89%) of
patients in the esmolol group vs in 162 of 208 (78%) of patients
in the metoprolol group (P < .05), whereas HR 60 beats/min
was reached in 147 of 204 (72%) of the patients who received
esmolol vs in 117 of 208 (56%) of patients who received
metoprolol (P < .001; Fig. 3).
None of the patients developed bradycardia (defined as
HR <50 beats/min) after b-blocker administration (minimum
HR in group esmolol was 53 beats/min; minimum HR in
group metoprolol was 52 beats/min). However, hypotension
(defined as systolic BP <100 mm Hg) was observed in 19Fig. 2 e The figure represents the mean heart rates and
their standard deviations in the esmolol and metoprolol
groups at different time points. The red triangles represent
the mean heart rates in the esmolol group, whereas the
black squares indicate the mean heart rates in the
metoprolol group. T1, time of arrival; T2, time point before
the coronary CT angiography (CTA) scan; TS, coronary
CTA scan; T3, time point immediately after the coronary
CTA; T4, 30 minutes after the coronary CTA. *P< .01;
***P< .0001. (For interpretation of the references to color in
this figure legend, the reader is referred to the Web version
of this article.)
Table 3 e Blood pressure.
Time point Esmolol
(n ¼ 204)
Metoprolol
(n ¼ 208)
P
Mean  SD Mean  SD
T1
Systole 142  22 146  21 .195
Diastole 87  12 87  12 .819
T2
Systole 144  21 145  20 .918
Diastole 86  13 87  12 .945
T3
Systole 128  20 131  19 .053
Diastole 74  12 75  12 .522
T4
Systole 132  20 134  21 .414
Diastole 79  11 80  12 .589
Blood pressure (in mm Hg) measured at T1 (arrival), T2 (before
scan), T3 (after scan), and T4 (emission).
Statistics: robust, independent t test.
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the metoprolol group right after the scan (T3; P < .05).
Importantly, only 5 patients (2.5%) had a systolic BP <100
mmHg 30 minutes after the scan (T4) in the esmolol group,
whereas the number of patients with hypotension remained 8
(3.8%) in the metoprolol group (P ¼ .418). None of the patients
required hospitalization or medical intervention due to
hypotension and the systolic BP normalized after a short
(maximum 2 hours) observation in every case. Of note, the
absolute time spent in the CT unit (T3eT2) did not differ be-
tween the esmolol and metoprolol group (21.1  7.5 vs 21.8 
7.9 minutes; P ¼ .428).Fig. 3 e The bar charts illustrate the proportion of patients
that reached a heart rate £60 beats/min (left side) and the
proportion of patients that reached a heart rate £65 beats/
min in the esmolol and metoprolol groups.4. Discussion
In this randomized, single-center clinical trial we compared IV
esmolol vs IV metoprolol for HR control in patients who
underwent coronary CTA because of suspected coronary
artery disease. We showed that esmolol with a stepwise bolus
administration protocol is at least as efficacious as the stan-
dard of care metoprolol to achieve the optimal HR (<65 beats/
min) during coronary CTA. Furthermore, we have demon-
strated that IV esmolol allows a safe HR control for coronary
CTA examination even if it is administered in relatively high
doses with a dosage scheme independent of body weight.
Esmolol is an ultrashort-acting intravenous b-blocker. The
rapid onset and offset of effects of esmolol make this intra-
venous drug a potential alternative of the standard of care
metoprolol in the daily routine coronary CTA service. Espe-
cially, coronary CTA services with no access to cardiology
or intensive care background might benefit most of this
ultrashort-acting medication. The recommended adminis-
tration protocol of IV esmolol with infusion pump is relatively
complex and precluded its widespread use in the diagnostic
facilities. Different dosage schedules have been developed
depending on clinical setting and diagnosis. Generally, a
loading dose of <500 mg/kg/min over 1 minute is administered
followed by a continuous infusion of 25e300 mg/kg/min.17 We
showed that esmolol is safe and efficacious if administered in
boluses without the subsequent continuous infusion. The
“bolus only” administration protocol of esmolol would make
this IV b-blocker a real life alternative of IV metoprolol. In this
clinical trial we used a body weighteindependent adminis-
tration protocol with stepwise increments in dose in every 3
minutes. Importantly, the timing of the administration of the
IV esmolol boli was similar to the metoprolol administration
protocol; therefore, it did not slow down our routine clinical
cardiac CT workflow. Our choice of 100-mg IV esmolol for the
initial bolus is based on a previous observational study that
showed that the dose of 2 mg/kg (for a 70-kg patient this
equals 140-mg esmolol) is safe to administer before the cor-
onary CTA examination.14 If 100-mg dose proved to be inef-
fective, thus the patient’s HR did not reach the predefined65
beats/min in 3 minutes, we have increased the bolus to
200-mg IV esmolol. Finally, if the HR did not change after
an additional 3-minute period (testing during a Valsalva
maneuver as well), we administered the third, once again
200-mg, bolus of IV esmolol. We have not added further
boluses; thus, the maximum administered IV esmolol was
500 mg during an approximately 6- to 7-minutes time period.
Of note, only about one-third of patients have received the full
dose of esmolol and two-thirds of patients have reached the
target HR with 300-mg esmolol dose. We have stopped the
patient enrollment early as the interim analysis indicated that
esmolol is clearly noninferior to metoprolol; in fact, it showed
superiority characteristics as the responder proportion in the
esmolol group was 89% vs the metoprolol group’s 78%.
Degertekin at al14 demonstrated the safety and efficacy
of IV esmolol in 391 patients. In this prospective study, HR
was reduced from 80  11 beats/min to 63  7 beats/min
and HR <65 beats/min was achieved in 65% of the patients.
Four of the 391 patients (1%) have experienced a final HR
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the bradycardia resolved in minutes without any intervention
with atropine or temporary pacing. Moreover, Degertekin
et al14 reported a 0.5% incidence of transient hypotension
(systolic BP<100mmHg). In our clinical trial, we have reached
a higher responder proportion (89.2%) probably because of a
more aggressive dosing scheme. Importantly, none of the 204
patients who received esmolol had severe bradycardia (mini-
mum HR was 53 beats/min). On the other hand, transient
hypotension (systolic BP<100mmHg) was observed in 9.3% of
the patients immediately after the scan in the esmolol group,
which was significantly higher compared to the metoprolol
group’s 3.8%. Importantly, 30 minutes after the scan this
decreased to 2.5% in the esmolol group, whereas in the
metoprolol group the percentage of patients with hypotension
did not change (3.8%). None of the patients had clinically
significant adverse event. Thus, the stepwise bolus adminis-
tration of esmolol is safe and it is well tolerated among
patients with normal left ventricular function scheduled
to undergo coronary CTA examination. Furthermore, our data
show that IV esmolol is at least as efficacious as IV metoprolol
to reach optimal HR during coronary CTA.
Many centers are reluctant to administer IV medication for
HR control during coronary CTA owing to the fear from
potential side effects. A recent study by Kassamali et al19
reported minor complications (transient hypotension) rela-
ted to IV metoprolol administration only in 1.47% and major
complications (not resolving with observation of analgesia) in
0.44% of patients who underwent coronary CTA. These results
demonstrate that IV metoprolol is a safe drug to use for this
purpose in patients with normal left ventricular function
although the studywas underpowered to assess for raremajor
complications.
Esmolol is metabolized via rapid hydrolysis by red blood
cell esterases, independent of the hepatic and renal func-
tion.20 It is routinely administered during perioperative
intensive care and before laryngoscopy and tracheal intuba-
tion procedures to prevent hypertension and tachycardia.21,22
In this clinical trial, we have excluded patients with contra-
indications to b-blockers such as asthma. However, it has
been demonstrated previously that esmolol is safe in bron-
chospastic diseases.23
There are some limitations of our study we have to
consider. This is a single-center study; therefore, the efficacy
and safety of the described esmolol bolus protocol has to be
evaluated in a multicenter randomized controlled trial. As the
administration protocols and the injected volumes were
different for the IV metoprolol and IV esmolol groups, it was
not feasible to blind the physicians to the drug they were
administering. The combined use of oral and IV b-blocker
protocols for HR control might limit the generalizability of our
results for IV-only protocols. Owing to the oral metoprolol
pretreatment, our findings do not demonstrate that esmolol IV
alone vs metoprolol IV is as or more effective for HR control.
However, it is important to note that the combined use of oral
and IV b-blockers is a widely used and effective strategy for HR
lowering before coronary CTA.6,24 In this scenario, esmolol is
at least as efficacious as IV metoprolol. The response rate to
oral metoprolol was relatively low in our study (162 of 574
[28%]), which might have been higher with the use of a moreaggressive administration regime (eg, 100-mg oral metoprolol
if HR >65 beats/min).17 Furthermore, we did not test smaller
doses of esmolol (eg, 50e100 mg), which might be equally
efficacious. Moreover, it is important to note that esmolol is
more expensive than IV metoprolol. However, the effective
and short duration of HR control achievable with esmolol
might result in wider usage of this IV b-blocker in cardiac CT
labors, which would increase the percentage of patients
scanned with optimal HR and improve the diagnostic perfor-
mance of CTA. A larger multicenter trial is warranted to
adequately explore the cost-effectiveness of esmolol use in
the coronary CTA laboratories.
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